BioLineRx Ltd. - American Depositary Shares (BLRX)
4.1700
-1.0800 (-20.57%)
NASDAQ · Last Trade: Jun 2nd, 1:24 PM EDT
Detailed Quote
Previous Close
5.250
Open
5.160
Bid
4.170
Ask
4.250
Day's Range
4.160 - 5.230
52 Week Range
2.300 - 35.60
Volume
585,547
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
24,207
Chart
About BioLineRx Ltd. - American Depositary Shares (BLRX)
Biolinerx Ltd is a biopharmaceutical company that focuses on the development of innovative therapies for cancer and other diseases. The company is engaged in the research and clinical development of a diverse pipeline of drug candidates, aiming to address unmet medical needs through cutting-edge technologies and unique approaches. Biolinerx collaborates with various academic institutions and industry partners to enhance its product offerings and accelerate the development of its therapeutic solutions, striving to improve patient outcomes and quality of life in the medical field. Read More
The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.
The CHIPS and Science Act, a landmark $280 billion initiative, is designed to bolster domestic semiconductor manufacturing, strengthen supply chain resilience, and advance technologies critical to national security. Peraso Inc. (NASDAQ: PRSO), whose fixed wireless access (FWA) solutions rely on cutting-edge semiconductors, stands to benefit significantly from this federal initiative.
CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda.
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
